Oct 2, 2026 3-5pm ET
Friday on The Robert Scott Bell Show:
Hour 1
We Cannot Trust the CDC Estimates of Flu Vaccine Effectiveness Epidemiologist Eyal Shahar argues that the CDC’s annual estimates of influenza vaccine effectiveness may be substantially distorted by methodological problems in the observational studies used to calculate them. His analysis focuses on a large 2022-2023 study from the CDC-affiliated VISION Vaccine Effectiveness Network, a season in which the vaccine was considered well matched to the dominant influenza strain. The study used a test-negative design, comparing vaccination rates among patients seeking medical care who tested positive or negative for influenza. Shahar identifies several potential sources of bias. First, vaccination occurred as the flu season progressed, meaning vaccinated and unvaccinated people were not equally distributed across periods of high and low infection risk. In the data he examines, 61% of unvaccinated encounters occurred during the high-risk October-December period compared with 47% among vaccinated patients, while vaccinated patients were disproportionately represented during the lower-risk January-March period. Shahar argues this calendar-time imbalance could make vaccination appear protective even if part of the difference resulted from changing background infection rates. He also challenges the study’s exclusion of influenza events occurring within 14 days after vaccination, arguing that this can introduce what epidemiologists call immortal-time bias. Nearly 2,000 outpatient encounters were excluded because vaccination occurred 1-13 days before the index date or vaccination status was unknown, although the published study did not separately report those categories. Shahar further points to healthy-vaccinee bias, in which vaccinated individuals may differ systematically from unvaccinated individuals in health status and behavior. Statistical adjustment reduced many of the reported effectiveness estimates, which he interprets as evidence that confounding was present, while arguing that residual confounding may remain. He also questions seemingly inconsistent findings, including lower estimated effectiveness against hospitalization than outpatient encounters and substantially stronger protection against hospitalization among older adults than younger adults. Finally, among hospitalized elderly influenza patients, mortality was 4.0% among vaccinated patients and 2.7% among unvaccinated patients, although the groups were not randomized and differed somewhat in baseline characteristics, so this comparison cannot establish whether vaccination affected mortality. Shahar concludes that the CDC-associated estimates should not be treated as precise causal measurements and advocates alternative observational designs. His article is a methodological critique rather than a new randomized trial, and his suggestion that bias might explain much or even all of the measured vaccine effectiveness is his interpretation of the evidence rather than a result directly demonstrated by the original VISION study.
Odds Of Losing Your Nails, Hair Rise With GLP-1 Use Two French studies presented at the European Academy of Dermatology and Venereology annual meeting suggest people taking GLP-1 medications may experience hair, scalp and nail problems more frequently than people with obesity or Type 2 diabetes who do not use the drugs. Researchers examined 1,904 people with obesity and/or Type 2 diabetes, including 575 GLP-1 users and 1,329 people who had never taken the medications. In the nail analysis, 66% of GLP-1 users reported some type of nail disorder compared with 53% of nonusers. Nail discoloration was reported by 46% of users compared with 17% of nonusers, and researchers calculated substantially higher odds of nail detachment among people receiving GLP-1 therapy. Because rapid weight loss itself can affect nails and hair, investigators separately examined participants who lost weight and still found higher rates among those using GLP-1 drugs. Interpretation remains complicated, however, because approximately half of GLP-1 users reported having nail problems before beginning treatment. After researchers attempted to adjust for preexisting nail conditions, GLP-1 users still had approximately two to three times greater odds of nail detachment or discoloration. A second analysis of the same population examined hair and scalp symptoms. Unusual hair loss was reported by 50% of GLP-1 users compared with 34% of nonusers, while reduced hair volume or density was reported by 42% versus 19%. Twenty-six percent of GLP-1 users reported unusual hair loss soon after beginning treatment compared with 12% of nonusers. Researchers also observed reports of scalp redness and itching, raising the possibility that some cases involve inflammation rather than solely the temporary hair shedding that can accompany rapid weight loss or nutritional changes. These studies do not establish that GLP-1 medications caused the abnormalities. They were observational, relied partly on participant reports and were presented at a medical meeting rather than published as completed peer-reviewed studies. Researchers are planning prospective work following patients from the beginning of GLP-1 treatment to better distinguish drug effects from weight loss, underlying disease, nutritional changes and preexisting dermatologic problems.
Dad Claims He Went Suddenly, Permanently Blind from Ozempic – in One of Hundreds of Lawsuits Against GLP-1 Makers Massachusetts father and longtime softball coach Edward Gillen, 59, is suing Novo Nordisk after experiencing sudden and permanent blindness that he alleges was caused by Ozempic, joining more than 200 plaintiffs pursuing claims involving GLP-1 medications and a rare optic-nerve condition. Gillen, who has diabetes, says he had taken Ozempic for approximately a year when he noticed a small visual disturbance around Memorial Day 2025. His eyesight deteriorated rapidly, and he says he was completely blind by June 1. After MRIs, CT scans and evaluation by a neuro-ophthalmologist, Gillen was diagnosed with nonarteritic anterior ischemic optic neuropathy, or NAION. The condition occurs when blood flow to the optic nerve is disrupted, producing sudden vision loss that is generally considered irreversible. Gillen alleges that Ozempic caused his NAION and that the manufacturer did not adequately warn patients about the potential risk. His case is part of expanding litigation involving GLP-1 manufacturers Novo Nordisk and Eli Lilly. The legal allegations should be distinguished from a scientific determination of causation. Diabetes, cardiovascular conditions and other characteristics common among GLP-1 users are themselves associated with NAION, complicating efforts to determine whether the medications independently increase risk. However, several recent observational studies have reported statistical associations between semaglutide, the active ingredient in Ozempic and Wegovy, and NAION, prompting additional regulatory and scientific attention. Such studies can identify a safety signal but cannot by themselves prove that semaglutide caused an individual patient’s vision loss. Novo Nordisk maintains that its GLP-1 medicines have been extensively studied and that their overall benefit-risk profile remains favorable when used appropriately. Gillen describes major changes to everyday life since losing his sight, including having to relearn routine tasks and giving up activities he previously performed independently. He has subsequently established the Coach BlindEd Foundation to support people experiencing vision loss and promote awareness and research. The litigation will ultimately have to address both whether GLP-1 treatment can causally contribute to NAION and whether manufacturers possessed sufficient evidence of a potential risk to require stronger warnings.
Copper Could Be a Secret Weapon Against Antibiotic-Resistant UTIs Researchers at Texas A&M University are investigating how the immune system uses copper as a natural antimicrobial weapon against urinary tract infections and whether that mechanism can be exploited to develop treatments for antibiotic-resistant bacteria. The project, supported by a $1.48 million National Institutes of Health grant, builds on previous work from veterinary pathobiologist Sarguru Subash showing that copper concentrations increase in the urinary tract during infection. Copper is an essential nutrient at low concentrations but can become toxic to microorganisms under specific conditions. Immune cells exploit this property by engulfing invading bacteria and exposing them to a combination of antimicrobial substances that includes copper. UTI-causing bacteria have nevertheless evolved mechanisms that allow them to tolerate or remove excess copper. Subash’s team plans to identify the genes and biological pathways responsible for this resistance, with the goal of finding ways to disable those defenses and make bacteria more vulnerable to both copper and other immune-system attacks. Researchers are also investigating preliminary evidence that copper interferes with fimbriae, the hairlike structures bacteria use to attach themselves to cells lining the bladder. Preventing attachment could be especially useful because bacteria unable to grip the bladder wall can be physically flushed from the urinary tract during urination. Another part of the project focuses on ceruloplasmin, a copper-containing protein that may help transport copper to infection sites. This mechanism must be carefully controlled because excessive copper can also damage human cells. The laboratory has already identified an experimental antimicrobial compound whose activity increases in the presence of copper and plans to test related compounds that might work synergistically with the body’s natural defenses. Researchers hope this approach could eventually produce treatments that do more than directly kill bacteria, instead weakening pathogens while strengthening mechanisms the immune system already uses. The research is still at an early preclinical stage, and Subash cautions that a copper-dependent UTI treatment suitable for patients is probably years away. The findings also do not mean that taking copper supplements will treat or prevent a UTI. The research concerns tightly regulated copper activity within the immune system and development of targeted antimicrobial therapies, not increasing dietary copper intake.
Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
Today’s Homeopathic Hit is Nuphar luteum, commonly known as Yellow Pond-lily.
Boericke highlights this remedy for nervous weakness with marked symptoms in the sexual sphere, including loss of desire, relaxed parts, impotency, spermatorrhoea, and involuntary emissions. Its bowel picture includes entero-colitis, yellow diarrhoea, morning aggravation, and diarrhoea during typhoid states.
Download the Information Sheet
Hour 2
ANH Uplevels the Fight to Protect Your Access to Homeopathic Medicines The Alliance for Natural Health USA and homeopathic manufacturer Meditrend Inc. have filed a Citizen Petition asking the FDA to restore a regulatory framework that for decades allowed qualifying homeopathic medicines to remain on the U.S. market without undergoing the standard new-drug approval process. From 1988 until its withdrawal in 2019, FDA Compliance Policy Guide 400.400 established conditions under which homeopathic products generally were not enforcement targets solely because they lacked FDA new-drug approval. The FDA replaced that system with a risk-based enforcement approach finalized in December 2022. ANH-USA argues that the newer policy leaves manufacturers without sufficiently predictable standards for determining whether otherwise compliant products will face enforcement. Its petition asks the FDA to reverse the 2019 withdrawal, reinstate CPG 400.400, suspend implementation of the 2022 framework and conduct formal notice-and-comment rulemaking to establish clearer standards. ANH-USA also challenges the FDA’s safety justification for treating the category broadly. A scientific exhibit accompanying the petition analyzes 2,068 adverse-event reports involving homeopathic or purportedly homeopathic products and argues that many serious incidents involved products that were contaminated, mislabeled, improperly manufactured, delivered through inappropriate routes or contained pharmacologically active quantities of ingredients. ANH-USA contends these cases justify targeted enforcement rather than regulatory uncertainty for the entire category. It proposes a “traffic-light” system under which properly manufactured, correctly labeled and low-risk products would receive green status and low enforcement priority; products presenting unresolved questions would receive amber status and additional scrutiny; and products involving contamination, adulteration, misbranding, pharmacologically active exposure or causally supported serious adverse events would receive red status and priority enforcement. Meditrend says the current uncertainty has already contributed to lost investment, ingredient-sourcing problems and manufacturing disruptions. The petition also raises an Administrative Procedure Act argument, asserting that FDA did not adequately account for industry’s decades-long reliance on the previous policy before withdrawing it. These are ANH-USA and Meditrend’s legal and scientific arguments, not findings that the FDA has accepted. The FDA retains authority over homeopathic products marketed as drugs, and the petition asks the agency to change how that authority is exercised rather than establishing a new regulatory standard itself.
Heavy Drinking Surges Among Americans in One Age Group as Other Generations Cut Back Alcohol consumption among Americans has begun declining after increases associated with the COVID-19 pandemic, but adults between 50 and 64 are moving in the opposite direction, according to research led by the University of Southern California’s Keck School of Medicine and published in Annals of Internal Medicine. Researchers analyzed National Health Interview Survey responses from 114,352 U.S. adults collected between 2018 and 2024. Across the overall adult population, alcohol use declined by nearly 2% between 2022 and 2024, while heavy drinking dropped more than 8%. Those reductions have not yet returned overall drinking to pre-pandemic levels. Younger generations showed some of the largest decreases: alcohol use among Gen Z adults fell more than 5%, while millennials reported approximately 17% less drinking between 2022 and 2024. Adults ages 50 to 64 showed a strikingly different pattern. Their overall alcohol use increased by nearly 4% between 2018 and 2024, while heavy drinking increased more than 36%. Researchers defined heavy drinking as five or more drinks in a day or at least 15 per week for men, and four or more in a day or at least eight per week for women. Women’s heavy drinking remains approximately 13% above its 2018 level despite a recent decline. Experts interviewed by Fox suggested that retirement, loss of daily structure, loneliness, grief, chronic pain, medical problems and psychological stress could contribute to increased drinking among older adults, although the study itself did not determine why consumption patterns changed. Aging also changes alcohol metabolism and can increase vulnerability to its effects. Researchers emphasized associations with liver disease and several cancers and noted that serious alcohol-related liver damage can develop before obvious symptoms appear. The study has important limitations. Drinking was self-reported, which can underestimate consumption, and researchers observed only two years of declining use after several years of increases. Lead author Brian Lee therefore described the recent nationwide decline as encouraging but cautioned that it is too early to conclude that America has entered a sustained downward trend in alcohol consumption.
Moody? Tired? Aggressive? You Could Have ‘Irritable Male Syndrome’ “Irritable male syndrome,” or IMS, is an informal term used to describe a cluster of emotional and behavioral changes in men that proponents associate with declining or fluctuating testosterone, stress and changes in brain chemistry. The phrase originated with reproductive biologist Gerald Lincoln, who reported behavioral changes in male Soay sheep as testosterone levels fell outside breeding season and coined the term in 2001. It was subsequently popularized in relation to humans by psychotherapist Jed Diamond. Symptoms attributed to IMS can include irritability, anger, nervousness, depression, fatigue, reduced motivation, diminished libido, emotional sensitivity and difficulty concentrating. Testosterone does influence sexual function, muscle mass, energy and aspects of mood, and clinically low testosterone can be associated with fatigue, reduced sexual desire and mood changes. However, IMS itself is not an officially recognized medical diagnosis, and experts caution against treating every episode of irritability or fatigue in middle-aged men as evidence of testosterone deficiency. Unlike the predictable hormonal cycle underlying premenstrual symptoms in women, testosterone changes in men generally occur more gradually with aging and can also be affected by sleep, obesity, illness, medications, psychological stress and lifestyle. The article emphasizes that the symptoms commonly attributed to IMS overlap with depression, anxiety, sleep disorders and numerous medical conditions. Consequently, testosterone testing and broader medical evaluation may be necessary before attributing symptoms to hormones. If genuine testosterone deficiency is identified, treatment can include addressing underlying health and lifestyle factors and, for appropriately selected patients, testosterone replacement therapy. Counseling or other mental-health treatment may also be useful when emotional or relationship problems are prominent. The larger message is that men should not dismiss persistent mood changes, exhaustion, reduced libido or unusual aggression as simply an unavoidable part of getting older. At the same time, “irritable male syndrome” should be understood as a descriptive concept rather than an established disease with a universally accepted diagnostic test or treatment protocol.
Low-Dose Radiation May Help Slow Knee Arthritis Low-dose radiation therapy is being investigated as a possible treatment for painful knee osteoarthritis, offering a potential middle ground for some patients between repeated pain medication and joint-replacement surgery. Research presented at the American Society for Radiation Oncology has examined whether carefully targeted radiation at doses far below those typically used to treat cancer can reduce the inflammatory processes contributing to osteoarthritis pain. In a randomized study involving people with mild-to-moderate knee osteoarthritis, participants receiving low-dose radiation experienced greater improvements in pain and physical function than participants receiving a sham procedure. The treatment involves several small radiation doses directed specifically at the affected knee rather than the substantially higher cumulative radiation exposure used to destroy tumors. Researchers believe the effect may result from low-dose radiation altering inflammatory signaling and immune-cell activity inside the joint rather than rebuilding damaged cartilage. This distinction is important because osteoarthritis involves structural deterioration of cartilage and other joint tissues, meaning pain relief does not necessarily mean the underlying damage has been reversed. Low-dose radiation for benign inflammatory and degenerative conditions has a longer history in parts of Europe, particularly Germany, but is rarely used for osteoarthritis in the United States. Researchers argue that modern radiation equipment permits considerably more precise targeting than older technology and could potentially limit exposure of surrounding tissues. Long-term safety remains one of the major unanswered questions. Any ionizing radiation carries a theoretical risk of inducing cancer, and determining the balance between that small potential long-term risk and symptomatic benefit will require larger studies and longer follow-up. Researchers are therefore particularly interested in identifying patients for whom the treatment might provide meaningful benefit while minimizing unnecessary exposure. The findings do not establish low-dose radiation as a replacement for exercise, weight management, physical therapy, medications, injections or joint surgery. Instead, they suggest a potentially useful additional option that warrants further clinical investigation, particularly for people with persistent osteoarthritis pain who have limited treatment alternatives.
Scientists Identify 485 Pesticide Chemicals With Potential Breast Cancer Links Researchers at the Silent Spring Institute have identified 485 chemicals used in pesticide formulations that have biological or experimental evidence relevant to breast cancer, highlighting what the researchers describe as important gaps in how pesticide ingredients are evaluated. The study, published in Environmental Health Perspectives, builds on previous work that catalogued more than 900 chemicals capable of producing mammary tumors in laboratory animals or altering hormones and biological pathways associated with breast cancer. Researchers compared that collection with more than a dozen U.S. government databases to determine where people might encounter the chemicals. Of the 485 chemicals identified in pesticide formulations, 145 are currently registered by the Environmental Protection Agency as active pesticide ingredients. The remainder include substances that can be classified as “inert” ingredients, a regulatory designation meaning they are not the ingredient intended to kill or control the targeted pest. “Inert” does not necessarily mean biologically inactive or harmless. The researchers argue that these ingredients generally receive less attention in pesticide safety assessments even though people are exposed to complete formulations. The analysis also found many of the identified chemicals in other sources, including consumer products, pharmaceuticals, drinking water, food and construction materials. Federal biomonitoring data indicated that 84 of the chemicals have been detected in human bodies. Organophosphate pesticides such as malathion were detected in more than 90% of the U.S. population in cited biomonitoring data, while DDT-related exposure was detected in more than 40% despite the pesticide having been banned in the United States decades ago. These findings do not demonstrate that all 485 chemicals cause breast cancer in humans or that ordinary exposure to a particular pesticide will produce cancer. Instead, the researchers created a screening framework identifying substances warranting closer investigation because of experimental carcinogenicity, hormonal activity or related biological evidence. They recommend greater testing of both active and other formulation ingredients, examination of cumulative exposures and epidemiological studies of populations with elevated pesticide exposure.
Religious Exemption Win in New Jersey: Man Fired Over COVID Vaccine Mandate Awarded $670,000 An Essex County, New Jersey, jury unanimously found in favor of former county groundskeeper Theodore “Teddy” DeBlasio after concluding that Essex County discriminated against him when it denied his request for a religious accommodation from its COVID-19 vaccination requirement and terminated his employment. The eight-member jury returned its verdict on September 25 and awarded DeBlasio more than $670,000 for lost wages and emotional harm, with attorneys’ fees still to be determined. According to the account published by Children’s Health Defense, which originally appeared through Innovative Parenting NJ and relies on information from DeBlasio’s attorneys, the case is believed to be New Jersey’s first jury verdict involving a COVID-19 vaccine religious-exemption dispute. Evidence presented at trial indicated that Essex County denied exemption requests submitted by some Christian and Catholic employees while approving requests from Muslim employees. DeBlasio, a Christian, worked primarily outdoors maintaining hospital grounds. His attorneys argued that Muslim healthcare workers who received accommodations were permitted to remain employed using masking and testing requirements, while DeBlasio was not offered a comparable arrangement. The jury concluded that the county’s handling of his accommodation constituted religious discrimination. The verdict is significant because federal employment law generally requires employers to reasonably accommodate an employee’s sincerely held religious practice unless doing so would create an undue hardship, but the outcome of an individual case depends heavily on the employer’s justification, the employee’s duties and whether comparable accommodation was available. The verdict does not establish that every employer vaccination mandate or denial of a religious exemption was unlawful. Instead, the jury determined that the facts of DeBlasio’s particular case supported his discrimination claim. The award also represents a jury verdict rather than a nationwide precedent governing other employers or jurisdictions, and post-trial motions or an appeal could still affect the ultimate outcome. The case nevertheless provides another example of pandemic-era employment policies being tested under existing federal protections against religious discrimination.
Remember Friends, The Power to Heal is Yours!
